Friday, 16 October 2026European Markets

AZELIS GROUP Stock 12.94% Up On Thursday

Loading stream...

(VIANEWS) - The Market ended the session with AZELIS GROUP (AZE.BR) rising 12.94% to €18.76 on Thursday while BEL 20 jumped 0.65% to €3,478.91.

About AZELIS GROUP

Azelis Group NV engages in the distribution of specialty chemicals and food ingredients in Belgium and internationally. It serves various segments in life sciences, including personal care, home care. industrial cleaning, pharmaceuticals, healthcare, food and nutrition, animal nutrition, agricultural, and environmental solutions; and industrial chemicals industry, such as CASE, advanced materials and additives, lubricants, metalworking fluids, electronics, essential and fine chemicals, textiles, leather, and paper applications. Azelis Group NV was founded in 1996 and is headquartered in Antwerp, Belgium.

Earnings Per Share

As for profitability, AZELIS GROUP has a trailing twelve months EPS of €0.76.

PE Ratio

AZELIS GROUP has a trailing twelve months price to earnings ratio of 24.68. Meaning, the purchaser of the share is investing €24.68 for every euro of annual earnings.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AZELIS GROUP's stock is considered to be overbought (>=80).

More news about AZELIS GROUP (AZE.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com